A Poly(amidoamine) Dendrimer-Based Drug Carrier for Delivering DOX to Gliomas Cells

Yan Li,Hai He,Wanliang Lu,Xinru Jia

DOI: https://doi.org/10.1039/c7ra00713b

IF: 4.036

2017-01-01

RSC Advances

Abstract:G4–FA–PEG/DOX with surface-modified PEG and FA and encapsulated DOX showed enhanced in vitro cytotoxicity and cellular uptake via FR-mediated endocytosis.

What problem does this paper attempt to address?

A poly(amidoamine) dendrimer-based nanocarrier conjugated with Angiopep-2 for dual-targeting function in treating glioma cells

zejun xu,yao wang,zhiyong ma,zhijian wang,yen wei,xinru jia

DOI: https://doi.org/10.1039/c5py01625h

IF: 4.6

2016-01-01

Polymer Chemistry

Abstract:A GSH sensitive nanocarrier (G4-DOX-Angiopep-PEG), with Angiopep-2 as a dual-targeting group and doxorubicin (DOX) as the therapy drug, was constructed by covalently conjugating them on the periphery of fourth generation PAMAM dendrimers (G4 PAMAM), aiming for an enhancement of BBB transportation and drug accumulation in glioma cells. It was found that the DOX release reached 44% with the concentration of GSH at 10 mM in the system, while only 3% DOX was released at pH 7.4 without GSH. The in vitro assay of transport across the BBB model showed that G4-DOX-Angiopep-PEG delivered 11% of DOX in a period of 12 h. The carrier could internalize into C6 glioma cells through low-density lipoprotein receptor-related protein (LRP)-mediated transcytosis. The accumulation of DOX in the tumor site was increased due to the targeting effects of Angiopep-2 via LRP-mediated endocytosis, which resulted in the volume of the avascular C6 glioma spheroids being effectively reduced in vitro.
A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.

Yan Li,Hai He,Xinru Jia,Wan-Liang Lu,Jinning Lou,Yen Wei

DOI: https://doi.org/10.1016/j.biomaterials.2012.02.004

IF: 14

2012-01-01

Biomaterials

Abstract:A pH-sensitive dual-targeting drug carrier (G4-DOX-PEG-Tf-TAM) was synthesized with transferrin (Tf) conjugated on the exterior and Tamoxifen (TAM) in the interior of the fourth generation PAMAM dendrimers for enhancing the blood–brain barrier (BBB) transportation and improving the drug accumulation in the glioma cells. It was found that, on average, 7 doxorubicine (DOX) molecules, over 30 PEG1000 and PEG2000 chains and one Tf group were bonded on the periphery of each G4 PAMAM dendrimer, while 29 TAM molecules were encapsulated into the interior of per dendrimer. The pH-triggered DOX release was 32% at pH 4.5 and 6% at pH 7.4, indicating a comparatively fast drug release at weak acidic condition and stable state of the carrier at physiological environment. The in vitro assay of the drug transport across the BBB model showed that G4-DOX-PEG-Tf-TAM exhibited higher BBB transportation ability with the transporting ratio of 6.06% in 3 h. The carrier was internalized into C6 glioma cells upon crossing the BBB model by the coactions of TfR-mediated endocytosis and the inhibition effect of TAM to the drug efflux transports. Moreover, it also displayed the in vitro accumulation of DOX in the avascular C6 glioma spheroids made the tumor volume effectively reduced.
Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.

Zhuojun Gu,Meng Wang,Qiongyan Fang,Huaiyu Zheng,Feiyue Wu,Dai Lin,Ying Xu,Yi Jin

DOI: https://doi.org/10.3109/03639045.2014.908899

IF: 3.727

2015-01-01

Drug Development and Industrial Pharmacy

Abstract:Context: Polyamidoamine (PAMAM) dendrimers have attracted lots of interest as drug carriers. And little study about whether pluronic-attached PAMAM dendrimers could be potential drug delivery systems has been carried on. Objective: Pluronic F127 (PF127) attached PAMAM dendrimers were designed as novel drug carriers. Methods: Two conjugation ratios of PF127-attached PAMAM dendrimers were synthesized. H-1 nuclear magnetic resonance (H-1-NMR), Fourier transform infrared spectrum (FTIR), element analysis and ninhydrin assay were used to characterize the conjugates. Size, zeta potential and critical micelle concentrations (CMC) were also detected. And DOX was incorporated into the hydrophobic interior of the conjugates. Studies on their drug loading and drug release were carried on. Furthermore, hemolysis and cytotoxicity assay were used to evaluate the toxicity of the conjugates. Results and discussion: PF127 was successfully conjugated to the fifth generation PAMAM dendrimer at two molar ratios of 19% and 57% (PF127 to surface amine per PAMAM dendrimer molecular). The conjugates showed an increased size and a reduced zeta potential. And higher CMC values were obtained than pure PF127. Compared with unconjugated PAMAM dendrimer, PF127 conjugation significantly reduced the hemolytic toxicity and cytotoxicity of PAMAM dendrimer in vitro. The encapsulation results showed that the ability to encapsulate DOX by the conjugate of 19% conjugation ratio was better than that of 57% conjugation ratio. And the maximum is similar to 12.87 DOX molecules per conjugate molecule. Moreover, the complexes showed a sustained release behavior compared to pure DOX. Conclusion: Findings from the in vitro study show that the PF127-attached PAMAM dendrimers may be potential carriers for drug delivery.
PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.

Hai He,Yan Li,Xin-Ru Jia,Ju Du,Xue Ying,Wan-Liang Lu,Jin-Ning Lou,Yan Wei

DOI: https://doi.org/10.1016/j.biomaterials.2010.09.002

IF: 14

2011-01-01

Biomaterials

Abstract:A dual-targeting drug carrier (PAMAM-PEG-WGA-Tf) based on the PEGylated fourth generation (G = 4.0) PAMAM dendrimer with transferrin (Tf) and wheat germ agglutinin (WGA) on the periphery and doxorubicin (DOX) loaded in the interior was synthesized and its BBB penetration and tumor targeting properties were explored. DLS and TEM measurements revealed the size of PAMAM-PEG-WGA-Tf was in the range of 14–20 nm. It reduced the cytotoxicity of DOX to the normal cells greatly, while efficiently inhibited the growth rate of the C6 glioma cells. The assay of transport across the BBB showed that PAMAM-PEG-WGA-Tf delivered 13.5% of DOX in a period of 2 h, demonstrating an enhanced transport ratio as compared to the ratio of 8% for PAMAM-PEG-WGA, 7% for PAMAM-PEG-Tf and 5% for free DOX in the same period of time. The accumulation of DOX in the tumor site was increased due to the targeting effects of both Tf and WGA, leading to the complete breakage of the avascular C6 glioma spheroids in vitro.
C(rgdyk)-Decorated Pluronic Micelles for Enhanced Doxorubicin and Paclitaxel Delivery to Brain Glioma.

Yukun Huang,Wenchao Liu,Feng Gao,Xiaoling Fang,Yanzuo Chen

DOI: https://doi.org/10.2147/ijn.s104162

IF: 7.033

2016-01-01

International Journal of Nanomedicine

Abstract:Brain glioma therapy is an important challenge in oncology. Here, doxorubicin (DOX) and paclitaxel (PTX)-loaded cyclic arginine-glycine-aspartic acid peptide (c(RGDyK))decorated Pluronic micelles (cyclic arginine- glycine-aspartic acid peptide-decorated Pluronic micelles loaded with doxorubicin and paclitaxel [RGD-PF-DP]) were designed as a potential targeted delivery system to enhance blood-brain barrier penetration and improve drug accumulation via integrin-mediated transcytosis/endocytosis and based on integrin overexpression in blood-brain barrier and glioma cells. The physicochemical characterization of RGD-PF-DP revealed a satisfactory size of 28.5 +/- 0.12 nm with uniform distribution and core-shell structure. The transport rates across the in vitro blood-brain barrier model, cellular uptake, cytotoxicity, and apoptosis of U87 malignant glioblastoma cells of RGD-PF-DP were significantly greater than those of non-c(RGDyK)-decorated Pluronic micelles. In vivo fluorescence imaging demonstrated the specificity and efficacy of intracranial tumor accumulation of RGD-PF-DP. RGD-PF-DP displayed an extended median survival time of 39 days, with no serious body weight loss during the regimen. No acute toxicity to major organs was observed in mice receiving treatment doses via intravenous administration. In conclusion, RGD-PF-DP could be a promising vehicle for enhanced doxorubicin and paclitaxel delivery in patients with brain glioma.
Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin.

Zhiqing Pang,Huile Gao,Yuan Yu,Liangran Guo,Jun Chen,Shuaiqi Pan,Jinfeng Ren,Ziyi Wen,Xinguo Jiang

DOI: https://doi.org/10.1021/bc200062q

IF: 4.7

2011-01-01

Bioconjugate Chemistry

Abstract:A brain drug delivery system for glioma chemotherapy based on transferrin-conjugated biodegradable polymersomes, Tf-PO-DOX, was made and evaluated with doxorubicin (DOX) as a model drug. Biodegradable polymersomes (PO) loaded with doxorubicin (DOX) were prepared by the nanoprecipitation method (PO-DOX) and then conjugated with transferrin (TO to yield Tf-PO-DOX with an average diameter of 107 nm and surface Tf molecule number per polymersome of approximately 35. Compared with PO-DOX and free DOX, Tf-PO-DOX demonstrated the strongest cytotoxicity against C6 glioma cells and the greatest intracellular delivery. It was shown in pharmacokinetic and brain distribution experiments that Tf-PO significantly enhanced brain delivery of DOX, especially the delivery of DOX into brain tumor cells. Pharmacodynamics results revealed a significant reduction of tumor volume and a significant increase of median survival time in the group of Tf-PO-DOX compared with those in saline control animals, animals treated with PO-DOX, and free DOX solution. By terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling, Tf-PO-DOX could extensively make tumor cell apoptosis. These results indicated that Tf-PO-DOX could significantly enhance the intracellular delivery of DOX in glioma and the chemotherapeutic effect of DOX for glioma rats.
Dendrimer Platforms for Targeted Doxorubicin Delivery-Physicochemical Properties in Context of Biological Responses

Magdalena Szota,Urszula Szwedowicz,Nina Rembialkowska,Anna Janicka-Klos,Daniel Doveiko,Yu Chen,Julita Kulbacka,Barbara Jachimska

DOI: https://doi.org/10.3390/ijms25137201

2024-06-29

Abstract:The unique structure of G4.0 PAMAM dendrimers allows a drug to be enclosed in internal spaces or immobilized on the surface. In the conducted research, the conditions for the formation of the active G4.0 PAMAM complex with doxorubicin hydrochloride (DOX) were optimized. The physicochemical properties of the system were monitored using dynamic light scattering (DLS), circular dichroism (CD), and fluorescence spectroscopy. The Quartz Crystal Microbalance with Dissipation Monitoring (QCM-D) method was chosen to determine the preferential conditions for the complex formation. The highest binding efficiency of the drug to the cationic dendrimer was observed under basic conditions when the DOX molecule was deprotonated. The decrease in the zeta potential of the complex confirms that DOX immobilizes through electrostatic interaction with the carrier's surface amine groups. The binding constants were determined from the fluorescence quenching of the DOX molecule in the presence of G4.0 PAMAM. The two-fold way of binding doxorubicin in the structure of dendrimers was visible in the Isothermal calorimetry (ITC) isotherm. Fluorescence spectra and release curves identified the reversible binding of DOX to the nanocarrier. Among the selected cancer cells, the most promising anticancer activity of the G4.0-DOX complex was observed in A375 malignant melanoma cells. Moreover, the preferred intracellular location of the complexes concerning the free drug was found, which is essential from a therapeutic point of view.
Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.

Saijie Zhu,Minghuang Hong,Guotao Tang,Lili Qian,Jiayuan Lin,Yanyan Jiang,Yuanying Pei

DOI: https://doi.org/10.1016/j.biomaterials.2009.10.044

IF: 14

2010-01-01

Biomaterials

Abstract:Partly PEGylated polyamidoamine (PAMAM) dendrimers were used as the carrier for tumor-selective targeting of the anticancer drug doxorubicin (DOX). Acid-sensitive cis-aconityl linkage or acid-insensitive succinic linkage was introduced between DOX and polymeric carriers to produce PPCD or PPSD conjugates, respectively. DOX release from PPCD conjugates followed an acid-triggered manner and increased with increasing PEGylation degree. In vitro cytotoxicity of PPCD conjugates against murine B16 melanoma cells increased with, while cellular uptake decreased with increasing PEGylation degree. PPSD conjugates released negligible drug at any tested pH condition and were less cytotoxic. Confocal laser scanning microscopy confirmed the acid-sensitive release of DOX from PPCD conjugates in the lysosomes and the entrance into nuclei. Pharmacokinetic and biodistribution studies demonstrated that increasing PEGylation degree resulted in reduced liver and splenic accumulation, longer circulation time and more tumor accumulation of the conjugates. Although PPSD conjugates showed more tumor accumulation than PPCD conjugates at the same PEGylation degree, the acid-sensitive DOX release from PPCD conjugates ensured higher concentration of free DOX in tumor and more pronounced antitumor activity. Besides, the antitumor activity of PPCD conjugates increased with increasing PEGylation degree. Overall, PPCD conjugate with the highest PEGylation would be a promising candidate for solid tumor therapy.
PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance

Rajeshkumar Anbazhagan,Ganesan Muthusamy,Rajakumari Krishnamoorthi,Swedha Kumaresan,Nagarajan Rajendra Prasad,Juin-Yih Lai,Jen-Ming Yang,Hsieh-Chih Tsai

DOI: https://doi.org/10.1002/bit.27645

Abstract:In this study, we prepared ferulic acid (FA) and paclitaxel (PTX) co-loaded polyamidoamine (PAMAM) dendrimers conjugated with arginyl-glycyl-aspartic acid (RGD) to overcome P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). FA was released in greater extent (80%) from the outer layer of the dendrimers compared with PTX (70%) from the interior of the dendrimers. FA improved intracellular availability of PTX via P-gp modulation in drug-resistant cells. In vitro drug uptake data show higher PTX delivery with RGD-PAMAM-FP than with PAMAM-FP in drug resistant KB CH-R 8-5 cell lines. This indicates that RGD facilitates intracellular PTX accumulation through active targeting in multidrug-resistant KB CH-R 8-5 cells. The terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick-end labeling assay data and membrane potential analysis in mitochondria confirm the enhanced anticancer potential of RGD-PAMAM-FP nanoaggregates in drug-resistant cells. We also confirmed by the increased protein levels of proapoptotic factors such as caspase 3, caspase 9, p53, and Bax after treatment with RGD-PAMAM-FP nanoaggregates and also downregulates antiapoptotic factors. Hence, FA-PTX co-loaded, RGD-functionalized PAMAM G4.5 dendrimers may be considered as an effective therapeutic strategy to induce apoptosis in P-gp-overexpressing, multidrug-resistant cells.
Enhanced Blood-Brain-barrier Penetrability and Tumor-Targeting Efficiency by Peptide-Functionalized Poly(amidoamine) Dendrimer for the Therapy of Gliomas

Changliang Liu,Zijian Zhao,Houqian Gao,Iman Rostami,Qing You,Xinru Jia,Chen Wang,Ling Zhu,Yanlian Yang

DOI: https://doi.org/10.7150/ntno.38954

2019-01-01

Nanotheranostics

Abstract:Glioblastoma is one of the most common primary tumor types of central nervous system (CNS) with high malignance and lethality. Although many treatment options are currently available, the therapy of brain cancers remains challenging because of blood-brain-barrier (BBB) which prevents most of the chemotherapeutics into the CNS. In this work, a poly(amidoamine) dendrimer-based carrier was fabricated and modified with angiopep-2 (Ang2) peptide that has been demonstrated to bind to low density lipoprotein receptor-relative protein-1 (LRP1) on the endothelial cells of BBB and could therefore induce BBB penetration of the carrier. To improve tumor-targeting effect towards the glioma sites, the dendrimer was simultaneously functionalized with an epidermal growth factor receptor (EGFR)-targeting peptide (EP-1) which was screened from a “one-bead one-compound” (OBOC) combinatorial library. EP-1 peptide was demonstrated to have high affinity and specificity to EGFR at both the molecular and cellular levels. The dual-targeting dendrimer exhibited outstanding BBB penetrability and glioma targeting efficiency both in vitro and in vivo, which strikingly enhanced the anti-gliomas effect of the drugs and prolonged the survival of gliomas-bearing mice. These results show the potential of the dual-targeting dendrimer-based carrier in the therapy of gliomas through enhancing BBB penetrability and tumor targeting.
Lactoferrin-Conjugated Biodegradable Polymersome Holding Doxorubicin and Tetrandrine for Chemotherapy of Glioma Rats

Zhiqing Pang,Liang Feng,Rongrong Hua,Jun Chen,Huile Gao,Shuaiqi Pan,Xinguo Jiang,Peng Zhang

DOI: https://doi.org/10.1021/mp100277h

2010-01-01

Molecular Pharmaceutics

Abstract:The blood-brain barrier (BBB) and multidrug resistance (MDR) are the main causes for poor prognosis of glioma patients after chemotherapy. To explore the way for settling this problem, in this study, a novel antitumor agent loaded drug delivery system, lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine (Lf-PO-Dox/Tet), integrating both BBB and glioma-targeting moiety and MDR inhibitor, was designed and its chemotherapy for glioma rats was evaluated. Biodegradable polymersome (PO) encapsulating both doxorubicin (Dox) and tetrandrine (Tet) was prepared by the thin-film hydration method (PO-Dox/Tet) and then conjugated with lactoferrin (Lf) to yield Lf-PO-Dox/Tet with an average diameter around 220 nm and surface Lf molecule number per polymersome around 40. Compared with PO-DOX, PO-Dox/Tet, and Lf-PO-Dox, Lf-PO-Dox/Tet demonstrated the strongest cytotoxicity against C6 glioma cells and the greatest uptake index by C6 cells. In vivo imaging analysis indicated that Lf-PO labeled with a near-infrared dye could enter the brain and accumulate at the tumor site. Pharmacokinetics and tissue distribution results also showed that Lf-PO-Dox/Tet accumulated more in the right hemisphere than other groups of polymersomes. Pharmacodynamics results revealed that tumor volume of the Lf-PO-Dox/Tet group was significantly smaller than that of other therapeutic groups, and the median survival time of Lf-PO-Dox/Tet group was longer than that of Lf-PO-Dox group and significantly longer than those of the other three therapeutic groups. These results suggested that Lf-PO-Dox/Tet could have therapeutic potential for gliomas.
Selective Cellular Uptake and Druggability Efficacy through Functionalized Chitosan-Conjugated Polyamidoamine (PAMAM) Dendrimers

Ye Hu,Jian Chen,Wenyan Hu

DOI: https://doi.org/10.3390/s24154853

2024-07-26

Abstract:Nanotechnology has ushered in significant advancements in drug design, revolutionizing the prevention, diagnosis, and treatment of various diseases. The strategic utilization of nanotechnology to enhance drug loading, delivery, and release has garnered increasing attention, leveraging the enhanced physical and chemical properties offered by these systems. Polyamidoamine (PAMAM) dendrimers have been pivotal in drug delivery, yet there is room for further enhancement. In this study, we conjugated PAMAM dendrimers with chitosan (CS) to augment cellular internalization in tumor cells. Specifically, doxorubicin (DOX) was initially loaded into PAMAM dendrimers to form DOX-loaded PAMAM (DOX@PAMAM) complexes via intermolecular forces. Subsequently, CS was linked onto the DOX-loaded PAMAM dendrimers to yield CS-conjugated PAMAM loaded with DOX (DOX@CS@PAMAM) through glutaraldehyde crosslinking via the Schiff base reaction. The resultant DOX@CS@PAMAM complexes were comprehensively characterized using Fourier-transform infrared (FTIR) spectroscopy, transmission electron microscopy (TEM), and dynamic light scattering (DLS). Notably, while the drug release profile of DOX@CS@PAMAM in acidic environments was inferior to that of DOX@PAMAM, DOX@CS@PAMAM demonstrated effective acid-responsive drug release, with a cumulative release of 70% within 25 h attributed to the imine linkage. Most importantly, DOX@CS@PAMAM exhibited significant selective cellular internalization rates and antitumor efficacy compared to DOX@PAMAM, as validated through cell viability assays, fluorescence imaging, and flow cytometry analysis. In summary, DOX@CS@PAMAM demonstrated superior antitumor effects compared to unconjugated PAMAM dendrimers, thereby broadening the scope of dendrimer-based nanomedicines with enhanced therapeutic efficacy and promising applications in cancer therapy.
DOX-loaded PEG-PLGA and Pluronic Copolymer Composite Micelles Enhances Cytotoxicity and the Intracellular Accumulation of Drug in DOX-resistant Tumor Cells.

Yuan-Yuan Diao,Min Han,Ping-Tian Ding,Da-Wei Chen,Jian-Qing Gao

DOI: https://doi.org/10.1691/ph.2010.9328

2010-01-01

Pharmazie

Abstract:In the present study, doxorubicin (DOX) loaded polyethyleneglycol-poly (DL-lactic-co-glycolic acid) micelle as well as composite micelles composed polyethyleneglycol- poly(DL-lactic-co-glycolic acid) (PEG-PLGA) and Pluronic 105 (P105) were constructed. The micelles, with diameter around 106 nm and 85 nm respectively, were prepared by solvent evaporation method. The results showed that the encapsulation of DOX in micelles could significantly enhance its cytotoxicity in a DOX resistant tumor cell line, K562/DOX. The combination of PEG-PLGA and Pluronic further improved both the tumor-suppressive activity and the intracellular accumulation of DOX, indicating that the composite micelles would be potential to reverse the multidrug resistance in tumor cells.
Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy

Jianfeng Li,Huiying Yang,Yujie Zhang,Xutao Jiang,Yubo Guo,Sai An,Haojun Ma,Xi He,Chen Jiang

DOI: https://doi.org/10.1021/acsami.5b07045

IF: 9.5

2015-01-01

ACS Applied Materials & Interfaces

Abstract:Ligand-mediated polymeric micelles have enormous potential for improving the efficacy of glioma therapy. Linear-dendritic drug-polymer conjugates composed of doxorubicin (DOX) and polyethylene glycol (PEG) were synthesized with or without modification of choline derivate (CD). The resulting MeO-PEG-DOX8 and CD-PEG-DOX8 could self-assemble into polymeric micelles with a nanosized diameter around 30 nm and a high drug loading content up to 40.6 and 32.3%, respectively. The optimized formulation 20% CD-PEG-DOX8 micelles had superior cellular uptake and antitumor activity against MeO-PEG-DOX8 micelles. The subcellular distribution using confocal study revealed that 20% CD-PEG-DOX8 micelles preferentially accumulated in the mitochondria. Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively. Biodistribution study showed the DOX concentration of 20% CD-PEG-DOX8 micelles treated group at 48 h was 2.37-fold higher than that of MeO-PEG-DOX8 micelles treated group at 48 h and was 24 fold-higher than that of DOX solution treated group at 24 h. CD-PEG-DOX8 micelles (20%) were well tolerated with reduced cardiotoxicity, as evaluated in the body weight change and HE staining studies, while they induced most significant antitumor activity with longest media survival time in an orthotopic mouse model of U87-luci glioblastoma model as displayed in the bioluminescence imaging and survival curve studies. Our findings consequently indicated that 20% CD-PEG-DOX8 micelles are promising drug delivery system for glioma chemotherapy.
Dual stimuli-responsive dendronized prodrug derived from poly(oligo-(ethylene glycol) methacrylate)-based copolymers for enhanced anti-cancer therapeutic effect

Qiang Luo,Ling Lin,Qiaorong Huang,Zhenyu Duan,Lei Gu,Hu Zhang,Zhongwei Gu,Qiyong Gong,Kui Luo

DOI: https://doi.org/10.1016/j.actbio.2022.02.033

IF: 10.633

2022-04-01

Acta Biomaterialia

Abstract:In this study, we developed an enzyme- and pH-responsive dendronized poly(oligo-(ethylene glycol) methacrylate) (pOEGMA)-doxorubicin (DOX) polymeric prodrug, which combined the pOEGMA structure with a degradable peptide dendron. The introduction of the dendron in the prodrug hindered the entanglement of brush oligo-(ethylene glycol) (OEG) chains, allowed the prodrug to possess dual stimuli-responsiveness, and mediated self-assembly of the polymeric prodrug to form stable nanoparticles (NPs). Brush conformation of polyethylene glycol (PEG) side chains endowed the NPs with long-term circulation with a half-life of 16.0 h. The dual-responsive dendritic structure enhanced cellular uptake of NPs and facilitated drug release in response to overexpressed cathepsin B and an acidic pH in the tumor microenvironment, resulting in an enhanced therapeutic effect with a tumor inhibition rate of 72.9% for 4T1 tumor-bearing mice. The NPs were demonstrated to possess great hemocompatibility and biosafety. Therefore, this strategy could provide great insight for the design of poly(oligo-(ethylene glycol) methacrylate)-based copolymers as drug delivery carriers.Statement of SignificanceWe propose a dual-stimuli-responsive dendronized strategy for improving the cancer therapeutic effect of the poly(oligo-(ethylene glycol) methacrylate) (pOEGMA)-based drug conjugates. The introduction of the functional dendron promotes self-assembly of the polymeric prodrug into nanoparticles, hindering the entanglement of brush oligo-(ethylene glycol) (OEG) chains in the conjugated drugs. The obtained poly OEGMA-GFLG-Dendron-NH-N=DOX nanoparticles maintains long circulation, while addresses the drug release issue due to the presence of high-density PEG. The drug delivery system exhibits a high therapeutic potentcy with negligible side effects.

engineering, biomedical,materials science, biomaterials
Controlled release of DOX mediated by glutathione and pH dual-responsive hollow mesoporous silicon coated with polydopamine graft poly(poly(ethylene glycol) methacrylate) nanoparticles for cancer therapy

Zi-Hao Zhou,Rui-Qian Zhang,Guo-Fu Jia,Yi-Hui Wang,Yan-Ling Luo,Feng Xu,Ya-Shao Chen

DOI: https://doi.org/10.1016/j.jtice.2020.10.023

IF: 5.477

2020-10-01

Journal of the Taiwan Institute of Chemical Engineers

Abstract:We prepared novel DOX-loaded HMSNs coated with PDA and PEGMA.High loading capacity and entrapment efficiency were due to incorporation of HMSNs.The material exhibited pH and GSH mediated DOX controlled release profiles.HMSNs function as drug storage platforms and PDA and PEGMA act as gatekeepers.The drug carriers have great potentials to mediate drug release for cancer therapy.The development of multifunctional nano-drug carriers has become one of the most effective and prevailing approaches to overcome the non-selectivity and low cell uptake efficiency of drugs, as well as various side effects of traditional chemotherapy drugs. Herein, we reported novel hollow mesoporous silica nanoparticles (HMSNs) coated with polydopamine (PDA) and poly(poly(ethylene glycol) methacrylate) (PPEGMA) (PPEGMA) for the treatment of cancer. The HMSNs mainly served as a warehouse loading anticancer drug doxorubicin (DOX); the covering of PDA acted as pH-sensitive gatekeepers to control the diffusion and/or release of DOX from HMSNs in different pH stimuli environments, whilst the grafting of PPEGMA on the surface of by disulfide bonds and atom transfer radical polymerization (ATRP) increased the stability under physiological conditions and showed reductant sensitive responsiveness. The PPEGMA had a high loading capacity and entrapment efficiency of drugs through loading twice but low cytotoxicity. The in vitro release results indicated that the PPEGMA exhibited a high sensitivity to pH and glutathione (GSH) due to the PDA coating and disulfide bonds, which could control DOX release as intelligent "switches". The drug-loaded formulations could better be taken up by the cells, formed a higher concentration of DOX in the cells, and produced more remarkable apoptosis, thus achieving better treatment of tumors with high therapy efficacy. Therefore, the developed multifunctional materials could be used as a promising nano-drug carrier for cancer treatment.

engineering, chemical
Stable Peptides Mediated Glioma Targeting Drug Delivery

Xiaoli Wei,Jie Gao,Changyou Zhan,Cao Xie,Man Ying,Weiyue Lu

DOI: https://doi.org/10.1016/j.nano.2015.12.309

2016-01-01

Nanomedicine

Abstract:The treatment of glioma is one of the most challenging tasks in clinic. As an intracranial tumor, glioma exhibits many distinctive characteristics from other tumors. In particular, various barriers including enzymatic barriers in the blood and brain capillary endothelial cells, blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) rigorously prevent drug and drug delivery systems from reaching the tumor site. To tackle this dilemma, we developed a liposomal formulation to circumvent multiple-barriers by modifying the liposome surface with proteolytically stable peptides, (D)CDX and c(RGDyK). (D)CDX is a D-peptide ligand of nicotine acetylcholine receptors (nAChRs) on the BBB, and c(RGDyK) is a ligand of integrin highly expressed on the BBTB and glioma cells. Lysosomal compartments of brain capillary endothelial cells are implicated in the transcytosis of those liposomes. However, both peptide ligands displayed exceptional stability in lysosomal homogenate, ensuring that intact ligands could exert subsequent exocytosis from brain capillary endothelial cells and glioma targeting. In the cellular uptake studies, dually labeled liposomes could target both brain capillary endothelial cells and tumor cells, effectively traversing the BBB and BBTB monolayers, overcoming enzymatic barrier and targeting three-dimensional tumor spheroids. Its targeting ability to intracranial glioma was further verified in vivo by ex vivo imaging and histological studies. As a result, doxorubicin liposomes modified with both (D)CDX and c(RGDyK) presented better anti-glioma effect with prolonged median survival of nude mice bearing glioma than did unmodified liposomes and liposomes modified with individual peptide ligand. In conclusion, the liposome suggested in the present study could effectively overcome multi-barriers and accomplish glioma targeted drug delivery, validating its potential value in improving the therapeutic efficacy of doxorubicin for glioma.
Drug Delivery: Gel–Liposome‐Mediated Co‐Delivery of Anticancer Membrane‐Associated Proteins and Small‐Molecule Drugs for Enhanced Therapeutic Efficacy (Adv. Funct. Mater. 16/2014)

tianyue jiang,ran mo,adriano bellotti,jianping zhou,zhen gu

DOI: https://doi.org/10.1002/adfm.201470099

IF: 19

2014-01-01

Advanced Functional Materials

Abstract:A programmed drug-delivery system that can transport different anticancer therapeutics to their distinct targets holds vast promise for cancer treatment. Herein, a core-shell-based nanodepot consisting of a liposomal core and a crosslinked-gel shell (designated Gelipo) is developed for the sequential and site-specific delivery (SSSD) of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and doxorubicin (Dox). As a small-molecule drug intercalating the nuclear DNA, Dox is loaded in the aqueous core of the liposome, while TRAIL, acting on the death receptor (DR) on the plasma membrane, is encapsulated in the outer shell made of crosslinked hyaluronic acid (HA). The degradation of the HA shell by HAase that is concentrated in the tumor environment results in the rapid extracellular release of TRAIL and subsequent internalization of the liposomes. The parallel activity of TRAIL and Dox show synergistic anticancer efficacy. The half-maximal inhibitory concentration (IC50) of TRAIL and Dox co-loaded Gelipo (TRAIL/Dox-Gelipo) toward human breast cancer (MDA-MB-231) cells is 83 ng mL(-1) (Dox concentration), which presents a 5.9-fold increase in the cytotoxicity compared to 569 ng mL(-1) of Dox-loaded Gelipo (Dox-Gelipo). Moreover, with the programmed choreography, Gelipo significantly improves the inhibition of the tumor growth in the MDA-MB-231 xenograft tumor animal model.
A γ-cyclodextrin-based metal-organic framework embedded with graphene quantum dots and modified with PEGMA via SI-ATRP for anticancer drug delivery and therapy

Qiaojuan Jia,Zhenzhen Li,Chuanpan Guo,Xiaoyu Huang,Yingpan Song,Nan Zhou,Minghua Wang,Zhihong Zhang,Linghao He,Miao Du

DOI: https://doi.org/10.1039/c9nr06195a

IF: 6.7

2019-11-21

Nanoscale

Abstract:The γ-cyclodextrin-based metal-organic framework (γ-CD-MOF) composite was designed and prepared toward targeted anticancer drug delivery and cancer therapy. Large amounts of graphene quantum dots (GQDs) were embedded in the γ-CD-MOF matrix (denoted as GQDs@γ-CD-MOF) to endow the γ-CD-MOF with strong fluorescence, which was then modified by pH responsive poly(ethyleneglycol)dimethacrylate (PEGMA) through surface initiated atom transfer radical polymerization (SI-ATRP) to fabricate the PEGMA@GQDs@γ-CD-MOF composite. Then, the cancer cell-targeted probe was obtained by immobilizing the AS1411 aptamer over it (denoted as AS1411@PEGMA@GQDs@γ-CD-MOF) and it exhibits pH-responsive release function and excellent targeting ability. Large amounts of antitumour drug, doxorubicin hydrochloride (DOX), could be encapsulated within this composite due to the chemical-rich functionality, and the resultant pH-responsive DOX delivery system (denoted as DOX/AS1411@PEGMA@GQDs@γ-CD-MOF) displayed a higher DOX loading of 89.1% with sustained release than the pristine γ-CD-MOF and GQDs@γ-CD-MOF. The targeting specificity investigation revealed that this DOX delivery system was effectively internalized via receptor mediated endocytosis with high selectivity. The in vivo antitumour study with tumour-bearing mice illustrated that the tumour growth can be effectively suppressed and partially ablated with negligible side effects after treatments. Therefore, the proposed AS1411@PEGMA@GQD@γ-CD-MOF composite is promising for effective DOX delivery and tumour growth inhibition both in vitro and in vivo, showing great potential for anticancer therapy.
131I-Labeled and DOX-loaded Multifunctional Nanoliposomes for Radiotherapy and Chemotherapy in Brain Gliomas

Gao Jingmei,Lei Fang,Dongdong Sun,Yuntian Shen,Y. Hu,Ning Li,Jin Chang,Wei Li,Jian Tan

DOI: https://doi.org/10.1016/j.brainres.2016.12.014

IF: 3.61

2020-01-01

Brain Research

Abstract:The codelivery of different therapeutics is a promising option because of its synergetic effects of drugs. In this study, a new combination therapy that used the doxorubicin-loaded and 131I-labeled nanoliposomes (131I-DOX-NL) was proposed to delay tumor growth of gliomas, which are characterized by significant mortality and morbidity. 131I-DOX-NL was constructed based on bovine serum albumin (BSA)-tailor made hydrophobic maleimide-functionalized poly(ε-caprolactone) (PCL) (Fig. 1) and was evaluated by cellular viability in vitro and by U87 xenograft models in vivo. Compared with using 131I-NL or DOX-NL alone, our experimental results show that 131I-DOX-NL exhibits similar high cellular uptake but enhanced efficacy to cure gliomas because of its codelivery of 131I and DOX. In the U87 mouse tumor models, the combination therapy resulted in higher survival rates of mice and smaller tumor sizes than monotherapy did alone. In conclusion, multifunctional nanoliposome 131I-DOX-NL is a good candidate for the codelivery of 131I-mediated radiotherapy and DOX-mediated chemotherapy due to its ability to inhibit U87 cell proliferation and tumor growth. 131I-DOX-NL can be used as a promising effective therapy for malignant gliomas and deserves further investigation.

A Poly(amidoamine) Dendrimer-Based Drug Carrier for Delivering DOX to Gliomas Cells

A poly(amidoamine) dendrimer-based nanocarrier conjugated with Angiopep-2 for dual-targeting function in treating glioma cells

A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.

Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.

PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.

C(rgdyk)-Decorated Pluronic Micelles for Enhanced Doxorubicin and Paclitaxel Delivery to Brain Glioma.

Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin.

Dendrimer Platforms for Targeted Doxorubicin Delivery-Physicochemical Properties in Context of Biological Responses

Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.

PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance

Enhanced Blood-Brain-barrier Penetrability and Tumor-Targeting Efficiency by Peptide-Functionalized Poly(amidoamine) Dendrimer for the Therapy of Gliomas

Lactoferrin-Conjugated Biodegradable Polymersome Holding Doxorubicin and Tetrandrine for Chemotherapy of Glioma Rats

Selective Cellular Uptake and Druggability Efficacy through Functionalized Chitosan-Conjugated Polyamidoamine (PAMAM) Dendrimers

DOX-loaded PEG-PLGA and Pluronic Copolymer Composite Micelles Enhances Cytotoxicity and the Intracellular Accumulation of Drug in DOX-resistant Tumor Cells.

Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy

Dual stimuli-responsive dendronized prodrug derived from poly(oligo-(ethylene glycol) methacrylate)-based copolymers for enhanced anti-cancer therapeutic effect

Controlled release of DOX mediated by glutathione and pH dual-responsive hollow mesoporous silicon coated with polydopamine graft poly(poly(ethylene glycol) methacrylate) nanoparticles for cancer therapy

Stable Peptides Mediated Glioma Targeting Drug Delivery

Drug Delivery: Gel–Liposome‐Mediated Co‐Delivery of Anticancer Membrane‐Associated Proteins and Small‐Molecule Drugs for Enhanced Therapeutic Efficacy (Adv. Funct. Mater. 16/2014)

A γ-cyclodextrin-based metal-organic framework embedded with graphene quantum dots and modified with PEGMA via SI-ATRP for anticancer drug delivery and therapy

131I-Labeled and DOX-loaded Multifunctional Nanoliposomes for Radiotherapy and Chemotherapy in Brain Gliomas